Immunotherapy for Behçet's disease

Int Rev Immunol. 1997;14(1):49-66. doi: 10.3109/08830189709116844.


Behçet's disease is an inflammatory disorder affecting many organs including the eye and one of the most common sight-threatening causes in countries around the Mediterranean basin and in the Asia including Japan, Korea and China. A number of clinical and laboratory findings suggest the significant involvement of the immune alterations in the pathophysiology and the pathogenic mechanisms of Behçet's disease. The immune alterations demonstrated in the disease include the alteration of the T cell circuitry and abnormal functions of the leukocyte. Because immunologic processes are believed to be in the chain of events in the manifestation of Behçet's disease, various agents capable of modulating the immune responses have been used to treat the disease. These drugs include corticosteroids, colchicine, cytotoxic agents, and immunophilin ligands (cyclosporine and FK506). This paper reviews the experimental and clinical investigations to analyze the immunopharmacological activities of these immunosuppressive agents in animal models and in patients with Behçet's disease.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Behcet Syndrome / drug therapy
  • Behcet Syndrome / immunology
  • Behcet Syndrome / therapy*
  • Colchicine / therapeutic use
  • Cyclosporine / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy*
  • Ligands
  • Tacrolimus / therapeutic use
  • Uveitis / drug therapy


  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Ligands
  • Cyclosporine
  • Colchicine
  • Tacrolimus